The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 18, 2017
Filed:
Feb. 28, 2011
Hans-guido Wendel, New York, NY (US);
Andrew L. Wolfe, New York, NY (US);
Konstantinos John Mavrakis, New York, NY (US);
Elisa Oricchio, New York, NY (US);
Adolfo A. Ferrando, New York, NY (US);
Kim DE Keersmaecker, Lueven, BE;
Teresa Palomero, New York, NY (US);
Franki Speleman, Ghent, BE;
Pieter Van Vlierberghe, Ghent, BE;
Hans-Guido Wendel, New York, NY (US);
Andrew L. Wolfe, New York, NY (US);
Konstantinos John Mavrakis, New York, NY (US);
Elisa Oricchio, New York, NY (US);
Adolfo A. Ferrando, New York, NY (US);
Kim De Keersmaecker, Lueven, BE;
Teresa Palomero, New York, NY (US);
Franki Speleman, Ghent, BE;
Pieter Van Vlierberghe, Ghent, BE;
Memorial Sloan Kettering Cancer Center, New York, NY (US);
Universiteit Gent, Ghent, BE;
Columbia University, New York, NY (US);
Abstract
The present invention relates to microRNAs (miRNAs) which are associated with cancer, particularly including hematologic malignancies, and particularly T-cell acute lymphoblastic leukemia (T-ALL), and to the assessment and modulation thereof in the treatment and management of cancer. The present invention is directed to methods and compositions for diagnosing and treating cancer, particularly T-ALL, by modulating miRNAs, and the use of miRNAs and antagonists thereof, particularly antagomirs, for predicting and assessing response to treatment, in assays for isolating and selecting antagonists, and as compositions for the treatment and management of cancer. Methods and compositions are provided for treatment or alleviation of cancer, particularly T-ALL, with antagonists/antagomirs of miRNAs, particularly one or more of miR-19b, miR-20a, miR26, miR92, miR148 and miR223.